Case: 1:19-op-45698-DAP Doc #: 20 Filed: 08/01/19 1 of 6. PageID #: 842 I hereby certify that this instrument is a true and correct copy of

I hereby certify that this instrument is a true and correct copy of the original on file in my office. Attest: Sandy Opacich, Clerk U.S. District Court, Northern District of Ohio



UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION

IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION

MDL No. 2804

TRANSFER ORDER

Before the Panel: * Plaintiffs in 43 actions move under Panel Rule 7.1 to vacate the orders conditionally transferring their respective actions listed on Schedule A to MDL No. 2804. Central District of California plaintiff United Healthcare Services, Inc., also requests establishment of a separate MDL consisting of claims against Insys Therapeutics, Inc., in the District of Arizona. Various defendants oppose the motions.

After considering the arguments of counsel, we find these actions involve common questions of fact with the actions previously transferred to MDL No. 2804, and that transfer under 28 U.S.C. § 1407 will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. Moreover, transfer is warranted for the reasons set forth in our order directing centralization. In that order, we held that the Northern District of Ohio was an appropriate Section 1407 forum for actions sharing factual questions regarding the allegedly improper marketing and distribution of various prescription opiate medications into states, cities, and towns across the country. *See In re Nat'l Prescription Opiate Litig.*, 290 F. Supp.3d 1375, 1378-79 (J.P.M.L. 2017).

Despite some variances among the actions before us, they share a factual core with the MDL actions: the manufacturer and distributor defendants' alleged knowledge of and conduct regarding the diversion of these prescription opiates, as well as the manufacturers' allegedly improper marketing of such drugs. *See id.* The actions therefore fall within the MDL's ambit.

^{*} Judges Ellen Segal Huvelle and Nathaniel M. Gorton did not participate in the decision of this matter.

Amerisourcebergen Corp. and Amerisourcebergen Drug Corp.; Cardinal Health, Inc., McKesson Corp. (distributor defendants); Allergan PLC, Allergan Finance, LLC; Actavis LLC, Actavis Pharma, Inc.; Barr Laboratories, Inc.; Cephalon, Inc.; Endo Health Solutions Inc., Endo Pharmaceuticals, Inc.; Insys Therapeutics, Inc.; Janssen Pharmaceutica, Inc.; Janssen Pharmaceuticals Inc.; Johnson & Johnson; Mallinckrodt plc; Mallinckrodt LLC; Ortho-McNeil-Jansenn Pharmaceuticals, Inc., Par Pharmaceutical Companies, Inc., Par Pharmaceutical, Inc., Par Pharmaceutical, Inc., Par Pharmaceutical Companies, Inc.; Purdue Pharma, Inc., and The Purdue Frederick Company, Inc.; Rhodes Pharmaceuticals; SpecGx LLC; Teva Pharmaceutical Industries Ltd.; Teva Pharmaceuticals USA, Inc., and Watson Laboratories, Inc. (manufacturing defendants).

-2-

The parties opposing transfer in 42 actions argue principally that federal jurisdiction is lacking over their cases. But opposition to transfer based on a jurisdictional challenge is insufficient to warrant vacating conditional transfer orders covering otherwise factually related cases.² Several parties also argue that including their actions in this large MDL will cause them inconvenience. Given the undisputed factual overlap with the MDL proceedings, transfer is justified in order to facilitate the efficient conduct of the litigation as a whole. *See In re Watson Fentanyl Patch Prods. Liab. Litig.*, 883 F. Supp. 2d 1350, 1351-52 (J.P.M.L. 2012) ("[W]e look to the overall convenience of the parties and witnesses, not just those of a single plaintiff or defendant in isolation.").

Central District of California plaintiff United HealthCare, which brings claims against Insys for its role in United's purported wrongful coverage of Subsys prescriptions, opposes transfer on the grounds that its action, *United Healthcare*, is unique. United also requests the creation of an Insys-only MDL. We deny the motion to vacate and the request to create a new MDL. Insys initiated Chapter 11 proceedings in early June 2019. Creating a new MDL is inadvisable at this time – no litigation is ongoing at the moment against Insys, pursuant to the automatic stay,³ and Insys has yet to weigh in on United's proposal. Further, the *United Healthcare* action shares significant factual overlap with many MDL actions. We recently transferred a third-party payor putative class action (of which United presumably would be a member), the crux of which was that Insys perpetrated a scheme to defraud third-party payors of prescription drugs by, among other things, impersonating physician office staff and falsifying patient records to induce third-party payors to pay for prescriptions of Subsys. *See* Transfer Order at 2, and *In re Nat'l Prescription Opiate Litig.*, MDL No. 2804 (J.P.M.L. June 5, 2019) (ECF No. 4537). Moreover, Insys and its role in the proliferation of Subsys is at issue in hundreds of actions brought by other MDL plaintiffs.

² See, e.g., In re Prudential Ins. Co. of Am. Sales Practices Litig., 170 F. Supp. 2d 1346, 1347-48 (J.P.M.L. 2001).

³ Where transfer is otherwise appropriate, the Panel transfers actions under Section 1407 even if those actions currently are stayed as the result of bankruptcy proceedings. *In re Ephedra Prods. Liab. Litig.*, 416 F. Supp. 2d 1358, 1359-60 (J.P.M.L. 2006) (transferring actions subject to bankruptcy stay). Section 1407 transfer does not affect the operation of the bankruptcy stay. Claims stayed in the transferor court remain stayed in the transferee court. The Panel is simply indicating the place where proceedings will occur when the stay is lifted. Any questions concerning the effect of the stay and any modification thereof are matters to be worked out by the involved courts and the parties.

IT IS THEREFORE ORDERED that the actions listed on Schedule A are transferred to the Northern District of Ohio and, with the consent of that court, assigned to the Honorable Dan A. Polster for inclusion in the coordinated or consolidated pretrial proceedings.

PANEL ON MULTIDISTRICT LITIGATION

Sarah S. Vance Chair

Lewis A. Kaplan Catherine D. Perry

R. David Proctor Karen K. Caldwell

IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION

MDL No. 2804

SCHEDULE A

Central District of California

UNITED HEALTHCARE SERVICES, INC. v. INSYS THERAPEUTICS, INC., C.A. No. 8:19-00545

Northern District of California

- COUNTY OF ALAMEDA, CALIFORNIA, ET AL. v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19–02307
- CITY OF COSTA MESA, ET AL. v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19-02320
- CITY OF FULLERTON, ET AL. v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19-02321
- CITY OF IRVINE, ET AL. v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19–02323 CITY OF SANTA ANA, ET AL. v. PURDUE PHARMA L.P., ET AL.,

C.A. No. 3:19-02324

- CITY OF WESTMINSTER, ET AL. v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19-02325
- CITY OF SAN CLEMENTE, ET AL. v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19–02326

District of Maryland

THE CITY OF ANNAPOLIS, MARYLAND v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19-01162

District of New Hampshire

STRAFFORD COUNTY v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–00325 BELKNAP COUNTY v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–00326 CHESHIRE COUNTY v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–00328 TOWN OF BELMONT, NH v. PURDUE PHARMA L.P., ET AL.,

C.A. No. 1:19-00329

CITY OF CLAREMONT, NH v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19-00331

GRAFTON COUNTY v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–00332 ROCKINGHAM COUNTY v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–00333 SULLIVAN COUNTY v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–00334

Eastern District of Oklahoma

PITTSBURG COUNTY BOARD OF COUNTY COMMISSIONERS v. PURDUE PHARMA, LP, ET AL., C.A. No. 6:19-00100

Northern District of Oklahoma

CITY OF OWASSO v. PURDUE PHARMA L.P., ET AL., C.A. No. 4:19-00171

Western District of Oklahoma

CITY OF YUKON v. PURDUE PHARMA LP, ET AL., C.A. No. 5:19–00280 CITY OF MUSTANG v. PURDUE PHARMA LP, ET AL., C.A. No. 5:19–00339 CITY OF MIDWEST CITY v. PURDUE PHARMA LP, ET AL., C.A. No. 5:19–00345 CITY OF ENID v. PURDUE PHARMA LP, ET AL., C.A. No. 5:19–00351

Southern District of Texas

COUNTY OF WALKER v. OPTUMRX, INC., ET AL., C.A. No. 4:19-01767

Eastern District of Virginia

- FAUQUIER COUNTY, VIRGINIA v. MALLINCKRODT LLC, ET AL., C.A. No. 1:19–00364
- BOARD OF SUPERVISORS, PRINCE WILLIAM COUNTY v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19-00365
- FAIRFAX COUNTY BOARD OF SUPERVISORS v. PURDUE PHARMA, L.P., ET AL., C.A. No. 1:19–00544
- CITY OF CHESAPEAKE, VIRGINIA v. ACTAVIS, LLC, ET AL., C.A. No. 2:19–00183
- ACCOMACK COUNTY, VIRGINIA v. PURDUE PHARMA, L.P., ET AL., C.A. No. 2:19–00184
- NORTHUMBERLAND COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19–00246

Western District of Virginia

- CITY OF BRISTOL, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 1:19–00011
- LOUISA COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19–00027
- MADISON COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 3:19–00028
- HALIFAX COUNTY, VIRGINIA v. PURDUE PHARMA, L.P., ET AL., C.A. No. 4:19-00021
- CITY OF LEXINGTON, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 6:19-00021
- ROCKBRIDGE COUNTY, VIRGINIA v. PURDUE PHARMA, L.P., ET AL.,

- C.A. No. 6:19-00025
- ROANOKE COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 7:19–00271
- CITY OF ROANOKE, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 7:19-00272
- CITY OF SALEM, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 7:19–00273
- ALLEGHANY COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 7:19–00275
- FRANKLIN COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 7:19-00302
- FLOYD COUNTY, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 7:19–00371
- CITY OF COVINGTON, VIRGINIA v. PURDUE PHARMA L.P., ET AL., C.A. No. 7:19–00372